Celsion Corporation to Continue Following Patients in Phase III OPTIMA Study for Overall Survival
04 août 2020 08h30 HE
|
Celsion CORP
Ongoing Analysis of Unblinded Study Data Suggests Data Maturity May be at Issue Cohort of 26 Consecutive Patient Deaths Differs Substantially from Predicted Behavior and from the Balance of the...
Celsion Corporation to Hold Conference Call to Discuss OPTIMA Study on Wednesday, July 15, 2020 at 11:00 a.m. Eastern Time
14 juil. 2020 08h30 HE
|
Celsion CORP
LAWRENCEVILLE, N.J., July 14, 2020 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) will host a conference call and webcast on Wednesday, July 15 at 11:00 a.m. Eastern time to discuss its...
Celsion CEO Issues Letter to Stockholders
03 mars 2020 08h30 HE
|
Celsion CORP
LAWRENCEVILLE, N.J., March 03, 2020 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a leading oncology drug development company, announces that Michael H. Tardugno, the company’s chairman,...
Celsion Announces Publication of Research on Fluorescence Imaging of ThermoDox® Uptake in International Journal of Hyperthermia
14 nov. 2019 08h00 HE
|
Celsion CORP
Independent Analysis Confirms Increasing Heating Time + ThermoDox® Improves Tumor Uptake of Drug, which may be visualized by real-time fluorescence imaging Study Confirms that ThermoDox® Can Deliver...
Celsion Corporation Reports Second Quarter 2019 Financial Results and Provides Business Update
14 août 2019 16h30 HE
|
Celsion CORP
First Pre-Planned Efficacy Analysis of the Phase III OPTIMA Study Planned for Mid-October Strong Balance Sheet Plus the Non-Dilutive Sale of $4 Million of New Jersey State Net Operating...
Celsion Announces Data Lock for First Interim Analysis in OPTIMA Phase III Study of ThermoDox® in Primary Liver Cancer
05 août 2019 09h00 HE
|
Celsion CORP
Independent Data Monitoring Committee to Meet in October to Evaluate Interim Trial Data LAWRENCEVILLE, N.J., Aug. 05, 2019 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), an oncology...
CELSION ANNOUNCES PUBLICATION OF THERMODOX® PHASE I CLINICAL STUDY RESULTS IN THE LANCET ONCOLOGY
10 juil. 2018 08h00 HE
|
Celsion CORP
– The TARDOX Study, in Collaboration with University of Oxford, Evaluates the Use of Focused Ultrasound in Combination with ThermoDox® to Treat Primary and Metastatic Liver Cancer – – Imaging...